In this series of articles, we address the key questions to ask at every step of the cycle to ensure that your KOL Management is focussed, compliant, mutually beneficial, and of true scientific value.

Streamlining KOL engagement, while effectively building and maintaining long and meaningful relationships, is a top priority for oncology pharma companies.